Growth Autonomy 2 Flashcards

1
Q

What are the members of the monomeric G proteins superfamily - Ras?

A

Rac

Rho

Rab

Arf

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Example what each of these are in the biochemical, structural homology of HRas, Kras 4a & b and, NRas.

G domain

C terminla domain

CAAX region

A
  • G domain: allows Ras proteins to act as monomeric gene proteins and contains death binding regions and various others so very conserved
  • C terminal domain: very little conserved, lots divergence, equally proficient at driving cell cycle
  • CAAX motif: localises Ras to membrane where it needs to be for its funcionality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Outline the Ras signalling cycle.

3 marks

A
  • Ras when bound to GDP is inactive when bound to GTP in active conformation. Will switch itself off by hydrolysing 2GTP so back to inactive shape
  • To cycle between conformations needs accessory proteins – guanine exchange factor (GEF) sos binds to ras and changes conformation to get rid of GTP and get GDP from cytosol
  • Needs help with hydrolysis as have poor intrinsic GTPASE activity – hydrolysis is induced by GAP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Outline the molecular basis of the G protein conformational change

3 marks

A
  • Binding of GTP crucial to conformational change
  • On GDP - Two regions known as switch regions in protein so cant bind to any effector molecules – GDP
  • Third phosphsate interacts with two highly conserved amino acids in switch region – causing massive conformational change in gene protein allowing it to interact with its effector e.g. pi3 kinase or raf
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which isoform of Ras is the most mutated and what does said mutation do?

A
  • KRas mutations have the highest incidence and they render Ras constituitively active by preventing GTP hydrolysis
  • Common point mutations alter AA residues at positions 12, 13 or 61
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the hotspot mutations in Ras?

2 marks

A

AA 12 or 13 - point mutation here causes massive effect on activity of ras

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do mutations in Ras render it constitutively active?

A

By preventing GTP hydrolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How can Ras be inappropriately activated?

A

GAP deletion or mutation

GAP deletion:

  • common GAP associated with RAS is neurofirbin

Mutation:

  • mutations in neurofribrim gene NF1 cause dysregulated cell growth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why is membrane localisation of ras important for its activity and how is it achieved?

4 marks

A
  • Important to be able to receive signals
  • Achieved by multi-step post-translational modifications
  • First step: addition of isoprenoid lipid (farnesyl isoprenoid) to CAAX by farnesyl transferase
  • Specified by variable region and CAAX motif
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How does the post-translation modifications of Ras proteins take place?

7 marks

A
  • 1st step occurs in cytosol and using substrate FFP enzyme farneyl transferasewill transfer farneysl onto csyteine of CAAX motif
  • Using lipid farnesyl Ras will translocate and acnhor to outside of ER membrane
  • Once anchored becomes substrate for enzyme Race which cleaves off 33 AA
  • ICMT then methylesterifies the carboxyl group [on membrane as both race and ICMT exclusively located on membrane]
  • Palmotiyl lipid group added by palmotyiltransferase onto Ras
  • Using farneysl and palmitoyl group, Ras will anchor onto membrane
  • ABOVE ONLY TRUE FOR NRAS, HRAS, KRAS4A
  • Not for Kras4B has lycine rich region in variable region - can sub for palmitoyl bit so Kras4b doesn’t have palmitoyl group
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What was seen in preclinical studies with farmesyl transferase inhbitors?

2 marks

A
  • Significant potency as an ant-cancer drug for wide panel cancer cell lines
  • Activity independent of Ras mutational status
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What was seen in in vivo models of farnesyl transferase inhibitors?

2 marks

A
  • Activity in xenograft tumours regardless of Ras mutation
  • Little toxicity when combined with toxic drug
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What was seen in clinical trials with FTIs?

1 marks

A
  • Patients showed little to no response or ad some stability for very short period of time
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why did patients react in certain way in the clinical trials with FTIs?

3 marks

A
  • Kras and Nras still being prenylated and localised from cells
  • Only Hras was actually farnesylated
  • Kras and Nras can be alternatively prenylated through addition of geranylgeranyl 20-carbon isprenoid moiety by GGTase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why couldn’t an anti-cancer drug for Kras be used?

A

Drugs too toxic as knocking out too many proteins can’t be used in clinic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How else can you target Ras that doesn’t involve knocking out Kras?

A

By targeting the substrates needed for prenylation

17
Q

What is one way you can target Ras prenylation - through the use of what known drugs?

3 marks

A
  • Statins - used to reduce CVD
  • Ras pathway makes cholesterol so can use Lovastatin to block 3-hydroxy-3methylglutaryl CoA reductase
  • This reduces mevalonate products i.e. FPP and GGPP needed for prenylation
18
Q

How can bisphosphates be used to inhibit prenylation?
2 marks

A
  • Inhibits isopentyl-PP siomerase and farneysl-PP synthase
  • (used in osteoporosis)
19
Q

What is the Kras binding problem?

A

Kras GTP pocket inaccesible due to high affinity for GTP as GTP binds to active KRAS

20
Q

What is the KRAS G12C opportunity?

4 marks

A
  • Found inhibtior that can bind to the cysteine of Krasg12c in its inactie form
  • Binding opens switch II pocket
  • Inhibitor covalently binds to cysteine and induces switch II pocket
  • Kras G12C irreversibly locked in inactive state
21
Q

In order to give Ras an inhibitor what needs to be known?

A

If a B-Raf mutation is present as that’s where activation is

22
Q

Which Raf kinases is the key target in drug therapy and why?

4 marks

A
  • B-raf
  • Found in 40-60% cutaneous melanomas
  • Inhibited by small molecule kinase inhibitors
  • Has substitutions of aline with glutamic acid at position 600
  • Mutation allows Raf to act as fully active monomer and doesn’t need to bind to Ras for permanent downstream signalling
23
Q

ACTIVE RECALL ON EXTRA READING NOW

A
24
Q
A
25
Q
A
26
Q
A
27
Q
A
28
Q
A